CS1 is a potent DNA Topo II α inhibitor. CS1 displays broad-spectrum in vitro antitumor effects, low toxicity in vivo and potential anti-multidrug resistance capabilities. CS1 leads to DNA damage, cell cycle arrest at G2/M phase and apoptosis^[1].

CS1 shows cytotoxicity with IC₅₀ values of 16.92 and 18.88 µM for MCF-7 and MCF7/ADR cells, respectively^[1]
. CS1 (10, 50, 100 µM) inhibits the activity of topoisomerase II α (Topo IIα)^[1].
CS1 (0-20 µM) shows antiproliferation activity in cancer cells^[1].
CS1 (2.5, 5, 10 µM) induces cell cycle arrest at the G2/M phase^[1].
CS1 (2.5, 5, 10 µM) induces cell apoptosis^[1].
CS1 (5, 10, 15 µM; 24 h) induces DNA breaks in MDA-MB-231 cells^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

CS1 (20 mg/kg; i.v.; every other day for two weeks) shows antitumor effects^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

252.26

C₁₆H₁₂O₃

1448009-94-6

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Shen Y, et al. CS1 is a novel topoisomerase IIα inhibitor with favorable drug resistance profiles. Biochem Biophys Res Commun. 2014; 453(3):302-8.